• Publications
  • Influence
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.
TLDR
A unique connection between MAS risk and chronic IL-18 is described, epithelial inflammasome hyperactivity is identified as a potential source, and the pathogenicity of free IL-16 is demonstrated, suggesting an IL- 18-driven pathway, complementary to the cytotoxic impairment of fHLH, with potential as a distinguishing biomarker and therapeutic target in MAS.
Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria
TLDR
A role of mitochondrial dysfunction in developing the premature aging phenotypes in HGPS cells is demonstrated and mitochondrial‐targeting antioxidant methylene blue is suggested as a promising therapeutic approach for HGPS.
Lamin A and microtubules collaborate to maintain nuclear morphology
TLDR
It is found that LA knockout cells exhibit a crescent shape morphology associated with the microtubule-organizing center, which ameliorates upon treatment with MT drugs, Nocodazole or Taxol, and describes a collaborative effort between LA and the MT network to maintain nuclear morphology.
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
TLDR
Synthetic lethality between decreased activity of cyclin-dependent kinases 4 and 6 and VHL inactivation is identified in two species (human and Drosophila) and across diverse human ccRCC cell lines in culture and xenografts.
Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, Venlafaxine
TLDR
A patient who suffered with headache for 6 years failing to respond to over 20 different medical treatments, but found drastic improvement and eventual resolution with Venlafaxine, hypothesize a chronic inflammatory mechanism driving new daily persistent headache pathology.
Methylene Blue Alleviates Nuclear and Mitochondrial Abnormalities in Hutchinson‐Gilford Progeria Syndrome
TLDR
A role of mitochondrial dysfunction in developing the premature aging phenotypes in HGPS cells is demonstrated and a mitochondrial‐targeting antioxidant methylene blue is suggested as a promising therapeutic for HGPS.